JP2011241218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011241218A5 JP2011241218A5 JP2011116089A JP2011116089A JP2011241218A5 JP 2011241218 A5 JP2011241218 A5 JP 2011241218A5 JP 2011116089 A JP2011116089 A JP 2011116089A JP 2011116089 A JP2011116089 A JP 2011116089A JP 2011241218 A5 JP2011241218 A5 JP 2011241218A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- polymer
- water
- value
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 32
- 230000002378 acidificating effect Effects 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 17
- 230000007935 neutral effect Effects 0.000 claims 15
- 229920001477 hydrophilic polymer Polymers 0.000 claims 11
- 239000011159 matrix material Substances 0.000 claims 9
- -1 dialkylaminoalkyl modified methacrylate Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 229940028937 divalproex sodium Drugs 0.000 claims 6
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 230000008961 swelling Effects 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 239000012445 acidic reagent Substances 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 3
- 230000007423 decrease Effects 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 238000007580 dry-mixing Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000008240 homogeneous mixture Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000004513 sizing Methods 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940114077 acrylic acid Drugs 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24467899A | 1999-02-04 | 1999-02-04 | |
| US09/244,678 | 1999-02-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596913A Division JP5420126B2 (ja) | 1999-02-04 | 2000-01-26 | ｐＨ非依存延長放出性医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011241218A JP2011241218A (ja) | 2011-12-01 |
| JP2011241218A5 true JP2011241218A5 (enExample) | 2012-08-02 |
| JP5420590B2 JP5420590B2 (ja) | 2014-02-19 |
Family
ID=22923698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596913A Expired - Lifetime JP5420126B2 (ja) | 1999-02-04 | 2000-01-26 | ｐＨ非依存延長放出性医薬組成物 |
| JP2011116089A Expired - Lifetime JP5420590B2 (ja) | 1999-02-04 | 2011-05-24 | ｐＨ非依存延長放出性医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596913A Expired - Lifetime JP5420126B2 (ja) | 1999-02-04 | 2000-01-26 | ｐＨ非依存延長放出性医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1146864B1 (enExample) |
| JP (2) | JP5420126B2 (enExample) |
| AT (1) | ATE424191T1 (enExample) |
| CA (1) | CA2361496C (enExample) |
| CY (1) | CY1108863T1 (enExample) |
| DE (1) | DE60041691D1 (enExample) |
| DK (1) | DK1146864T3 (enExample) |
| ES (1) | ES2321908T3 (enExample) |
| PT (1) | PT1146864E (enExample) |
| WO (1) | WO2000045793A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6528090B2 (en) | 1998-12-18 | 2003-03-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US20020025341A1 (en) * | 1998-12-18 | 2002-02-28 | Yihong Qiu | Controlled release formulation of divalproex sodium |
| US6419953B1 (en) | 1998-12-18 | 2002-07-16 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6511678B2 (en) | 1998-12-18 | 2003-01-28 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| WO2002051402A1 (en) * | 2000-12-22 | 2002-07-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
| WO2004071421A2 (en) * | 2003-02-05 | 2004-08-26 | Teva Pharmaceutical Industries Ltd. | Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds |
| US8920837B2 (en) | 2005-07-01 | 2014-12-30 | Rubicon Research Private Limited | Sustained release dosage form |
| US20100255099A1 (en) * | 2007-10-26 | 2010-10-07 | Rexahn Pharmaceuticals, Inc. | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
| CN107811985B (zh) * | 2016-09-13 | 2021-05-28 | 四川科瑞德制药股份有限公司 | 一种抗癫痫缓释制剂及其制备方法与用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72381A (en) * | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| DE3809764A1 (de) * | 1988-03-23 | 1989-10-05 | Knoll Ag | Mischung aus alginaten und polyacrylaten und deren verwendung |
| FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| AU6824996A (en) * | 1995-08-17 | 1997-03-12 | Dyer, Alison Margaret | Controlled release products |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| CA2254078A1 (en) * | 1997-03-11 | 1998-09-17 | Hexal Ag | Solid, non-deliquescent formulations of sodium valproate |
-
2000
- 2000-01-26 WO PCT/US2000/001954 patent/WO2000045793A1/en not_active Ceased
- 2000-01-26 JP JP2000596913A patent/JP5420126B2/ja not_active Expired - Lifetime
- 2000-01-26 EP EP00904586A patent/EP1146864B1/en not_active Expired - Lifetime
- 2000-01-26 AT AT00904586T patent/ATE424191T1/de active
- 2000-01-26 DK DK00904586T patent/DK1146864T3/da active
- 2000-01-26 PT PT00904586T patent/PT1146864E/pt unknown
- 2000-01-26 CA CA2361496A patent/CA2361496C/en not_active Expired - Fee Related
- 2000-01-26 ES ES00904586T patent/ES2321908T3/es not_active Expired - Lifetime
- 2000-01-26 DE DE60041691T patent/DE60041691D1/de not_active Expired - Lifetime
-
2009
- 2009-03-06 CY CY20091100254T patent/CY1108863T1/el unknown
-
2011
- 2011-05-24 JP JP2011116089A patent/JP5420590B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011241218A5 (enExample) | ||
| Jana et al. | Interpenetrating hydrogels of O-carboxymethyl Tamarind gum and alginate for monitoring delivery of acyclovir | |
| CN102657629B (zh) | 替卡格雷缓释片系统及其制备方法 | |
| RS51527B2 (sr) | Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena | |
| CN101904818B (zh) | 自组装复合物膜控缓释制剂及其制备方法 | |
| MX2007008162A (es) | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. | |
| CN103550165A (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
| HRP20100676T1 (hr) | Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja | |
| WO2022012172A1 (zh) | 一种难溶性药物口服缓释组合物及其制备方法 | |
| Olayemi et al. | Formulation and evaluation of Cyperus esculentus (Tiger Nut) starch-alginate microbeads in the oral delivery of ibuprofen | |
| JP2014530802A5 (enExample) | ||
| CN101347413B (zh) | 喹硫平缓释片及其制备方法 | |
| JP2002536318A5 (enExample) | ||
| CN103520169B (zh) | 米氮平片及其制备方法 | |
| Rasool et al. | Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. | |
| CN103263395A (zh) | 一种替米沙坦片剂及其制备方法 | |
| CN104814923A (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
| CA2361496A1 (en) | Ph independent extended release pharmaceutical formulation | |
| CN104337787A (zh) | 含有利伐沙班的药物制剂 | |
| JP2017520619A5 (enExample) | ||
| CN107375223A (zh) | 含莱菔素胃滞留组合物及其制备方法 | |
| WO2009040388A1 (en) | Controlled release tamsulosin hydrochloride tablets and a process of making them | |
| Nokhodchi et al. | Application of polymer combinations in extended release hydrophilic matrices | |
| WO2011026312A1 (zh) | 一种含有美托洛尔琥珀酸盐的新型骨架缓释片 | |
| CN102727453A (zh) | 一种布南色林分散片及其制备方法 |